$6.11
2.00% yesterday
Nasdaq, Dec 24, 07:54 pm CET
ISIN
US92764N1028
Symbol
VIR

Vir Biotechnology Inc Stock price

$6.11
-0.01 0.16% 1M
+0.84 15.94% 6M
-1.23 16.76% YTD
-1.27 17.21% 1Y
-19.62 76.25% 3Y
-23.43 79.32% 5Y
+2.42 65.58% 10Y
+2.42 65.58% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.12 2.00%

Key metrics

Basic
Market capitalization
$850.1m
Enterprise Value
$343.5m
Net debt
positive
Cash
$506.5m
Shares outstanding
139.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
50.4 | 132.5
EV/Sales
20.4 | 53.5
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
82.2%
Return on Equity
-45.4%
ROCE
-58.5%
ROIC
-109.3%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$16.9m | $6.4m
EBITDA
$-541.0m | $-529.9m
EBIT
$-552.7m | $-538.7m
Net Income
$-499.7m | $-482.0m
Free Cash Flow
$-460.4m
Growth (TTM | estimate)
Revenue
-78.6% | -91.4%
EBITDA
2.4% | 4.0%
EBIT
3.1% | 2.4%
Net Income
6.3% | 7.7%
Free Cash Flow
2.7%
Margin (TTM | estimate)
Gross
95.9%
EBITDA
-3,208.9% | -8,257.0%
EBIT
-3,278.1%
Net
-2,963.5% | -7,510.6%
Free Cash Flow
-2,730.9%
More
EPS
$-3.6
FCF per Share
$-3.3
Short interest
12.9%
Employees
408
Rev per Employee
$180.0k
Show more

Is Vir Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Vir Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Vir Biotechnology Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Vir Biotechnology Inc forecast:

Buy
93%
Hold
7%

Financial data from Vir Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
17 17
79% 79%
100%
- Direct Costs 0.68 0.68
29% 29%
4%
16 16
79% 79%
96%
- Selling and Administrative Expenses 95 95
30% 30%
564%
- Research and Development Expense 474 474
8% 8%
2,810%
-541 -541
2% 2%
-3,209%
- Depreciation and Amortization 12 12
27% 27%
69%
EBIT (Operating Income) EBIT -553 -553
3% 3%
-3,278%
Net Profit -500 -500
6% 6%
-2,964%

In millions USD.

Don't miss a Thing! We will send you all news about Vir Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vir Biotechnology Inc Stock News

Neutral
Business Wire
9 days ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Company has granted Norgine Pharma UK Limited, an affiliate of Norgine, a leading European specialty pharmaceutical company, an exclusive license for the commercial rights to the combination of tobevibart and elebsiran for the treatment of chronic hepatitis delta (CHD) in Europe, Australia and New Zea...
Neutral
Business Wire
about one month ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3 at 10:50 a.m. ET / 7:50 a.m. PT in Miami, Florida. A live webcast of the presentation will be made available under Events & Present...
Neutral
Business Wire
about 2 months ago
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company's Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not detected (TND), inc...
More Vir Biotechnology Inc News

Company Profile

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Head office United States
CEO Marianne Backer
Employees 408
Founded 2016
Website www.vir.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today